{"DataElement":{"publicId":"6474219","version":"1","preferredName":"Accelerated Phase Chronic Myelogenous Leukemia Cytogenetic Response Type","preferredDefinition":"CML Accelerated phase criteria type","longName":"ACCL_CRIT","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"3854990","version":"1","preferredName":"Accelerated Phase Chronic Myelogenous Leukemia Cytogenetic Response","preferredDefinition":"A phase of chronic myelogenous leukemia characterized by one or more of the following: 1) Myeloblasts accounting for 10-19% of the peripheral blood white cells or of the nucleated cells in the bone marrow, 2) peripheral blood basophils at least 20%, 3) persistent thrombocytopenia that is unrelated to therapy, 4) persistent thrombocytosis despite adequate therapy, 5) increasing white blood cell count and increasing spleen size unresponsive to therapy, and/or evidence of clonal evolution. (WHO, 2001)_The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"3854988v1.0:3853590v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"3854988","version":"1","preferredName":"Accelerated Phase Chronic Myelogenous Leukemia Response","preferredDefinition":"A phase of chronic myelogenous leukemia characterized by one or more of the following: 1) Myeloblasts accounting for 10-19% of the peripheral blood white cells or of the nucleated cells in the bone marrow, 2) peripheral blood basophils at least 20%, 3) persistent thrombocytopenia that is unrelated to therapy, 4) persistent thrombocytosis despite adequate therapy, 5) increasing white blood cell count and increasing spleen size unresponsive to therapy, and/or evidence of clonal evolution. (WHO, 2001):The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C3173:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3173","definition":"A phase of chronic myeloid leukemia characterized by one or more of the following: 1) Myeloblasts accounting for 10-19% of the peripheral blood white cells or of the nucleated cells in the bone marrow, 2) peripheral blood basophils at least 20%, 3) persistent thrombocytopenia that is unrelated to therapy, 4) persistent thrombocytosis despite adequate therapy, 5) increasing white blood cell count and increasing spleen size unresponsive to therapy, and/or evidence of clonal evolution. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-89C5-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"ONEDATA","dateModified":"2013-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3853590","version":"1","preferredName":"Cytogenetic Analysis Evaluation","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"C18280:C25214","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3CB76BD-D0EF-2626-E040-BB89AD436DA7","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"ONEDATA","dateModified":"2013-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E3DF4512-89D3-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"KNABLEJ","dateModified":"2017-08-23","changeDescription":"8/23/17 jk transferred context and added registration status, CSI per Round 5 finalization task.  8/13/13 mc Created for CRF Harmonization per request by Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6474192","version":"1","preferredName":"Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6474192v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"5000","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Additional clonal chromosomal abnormalities in Ph+ cells at diagnosis that include major route abnormalities (second Ph, trisomy 8, isochromosome 17q, trisomy 19), complex karyotype or abnormalities of 3q26.2","valueDescription":"Additional clonal chromosomal abnormalities in Ph+ cells at diagnosis that include  major route  abnormalities (second Ph, trisomy 8, isochromosome 17q, trisomy 19), complex karyotype or abnormalities of 3q26.2","ValueMeaning":{"publicId":"6474194","version":"1","preferredName":"Additional clonal chromosomal abnormalities in Ph+ cells at diagnosis that include  major route  abnormalities (second Ph, trisomy 8, isochromosome 17q, trisomy 19), complex karyotype or abnormalities of 3q26.2","longName":"6474194","preferredDefinition":"Additional clonal chromosomal abnormalities in Ph+ cells at diagnosis that include  major route  abnormalities (second Ph, trisomy 8, isochromosome 17q, trisomy 19), complex karyotype or abnormalities of 3q26.2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77CD6FA1-20FC-3BAF-E053-F662850ACA8E","latestVersionIndicator":"Yes","beginDate":"2018-10-09","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-09","modifiedBy":"SENTINEL","dateModified":"2018-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B1E7057-190A-6000-E053-F662850AC472","beginDate":"2018-10-09","endDate":null,"createdBy":"LEEW","dateCreated":"2018-11-20","modifiedBy":"ONEDATA","dateModified":"2018-11-20","deletedIndicator":"No"},{"value":"Any new clonal chromosomal abnormality in Ph+ cells that occurs during therapy","valueDescription":"Any new clonal chromosomal abnormality in Ph+ cells that occurs during therapy","ValueMeaning":{"publicId":"6474193","version":"1","preferredName":"Any new clonal chromosomal abnormality in Ph+ cells that occurs during therapy","longName":"6474193","preferredDefinition":"Any new clonal chromosomal abnormality in Ph+ cells that occurs during therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77CD6FA1-20D9-3BAF-E053-F662850ACA8E","latestVersionIndicator":"Yes","beginDate":"2018-10-09","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-09","modifiedBy":"ONEDATA","dateModified":"2018-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77CD6FA1-20F2-3BAF-E053-F662850ACA8E","beginDate":"2018-10-09","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-09","modifiedBy":"ONEDATA","dateModified":"2018-10-09","deletedIndicator":"No"},{"value":"10%-19% blasts in the peripheral blood or bone marrow","valueDescription":"10%-19% blasts in the peripheral blood or bone marrow","ValueMeaning":{"publicId":"6474195","version":"1","preferredName":"10%-19% blasts in the peripheral blood or bone marrow","longName":"6474195","preferredDefinition":"10%-19% blasts in the peripheral blood or bone marrow","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77CD6FA1-211F-3BAF-E053-F662850ACA8E","latestVersionIndicator":"Yes","beginDate":"2018-10-09","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-09","modifiedBy":"ONEDATA","dateModified":"2018-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77CD6FA1-2138-3BAF-E053-F662850ACA8E","beginDate":"2018-10-09","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-09","modifiedBy":"ONEDATA","dateModified":"2018-10-09","deletedIndicator":"No"},{"value":"20% or more basophils in the peripheral blood","valueDescription":"20% or more basophils in the peripheral blood","ValueMeaning":{"publicId":"6474196","version":"1","preferredName":"20% or more basophils in the peripheral blood","longName":"6474196","preferredDefinition":"20% or more basophils in the peripheral blood","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77CD6FA1-2142-3BAF-E053-F662850ACA8E","latestVersionIndicator":"Yes","beginDate":"2018-10-09","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-09","modifiedBy":"ONEDATA","dateModified":"2018-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77CD6FA1-215B-3BAF-E053-F662850ACA8E","beginDate":"2018-10-09","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-09","modifiedBy":"ONEDATA","dateModified":"2018-10-09","deletedIndicator":"No"},{"value":"Persistent or increasing splenomegaly, unresponsive to therapy","valueDescription":"Persistent or increasing splenomegaly, unresponsive to therapy","ValueMeaning":{"publicId":"6474199","version":"1","preferredName":"Persistent or increasing splenomegaly, unresponsive to therapy","longName":"6474199","preferredDefinition":"Persistent or increasing splenomegaly, unresponsive to therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77CD6FA1-21AB-3BAF-E053-F662850ACA8E","latestVersionIndicator":"Yes","beginDate":"2018-10-09","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-09","modifiedBy":"ONEDATA","dateModified":"2018-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77CD6FA1-21C4-3BAF-E053-F662850ACA8E","beginDate":"2018-10-09","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-09","modifiedBy":"ONEDATA","dateModified":"2018-10-09","deletedIndicator":"No"},{"value":"Persistent thrombocytopenia (less than 100 x 10^9/L) unrelated to therapy","valueDescription":"Persistent thrombocytopenia (less than 100 x 10^9/L) unrelated to therapy","ValueMeaning":{"publicId":"6584056","version":"1","preferredName":"Persistent thrombocytopenia (less than 100 x 10^9/L) unrelated to therapy","longName":"6584056","preferredDefinition":"Persistent thrombocytopenia (less than 100 x 10^9/L) unrelated to therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C70AFCA-0ABE-49C0-E053-F662850AB2D3","latestVersionIndicator":"Yes","beginDate":"2018-12-07","endDate":null,"createdBy":"LEEW","dateCreated":"2018-12-07","modifiedBy":"ONEDATA","dateModified":"2018-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C70AFCA-0AD7-49C0-E053-F662850AB2D3","beginDate":"2018-12-07","endDate":null,"createdBy":"LEEW","dateCreated":"2018-12-07","modifiedBy":"ONEDATA","dateModified":"2018-12-07","deletedIndicator":"No"},{"value":"Persistent thrombocytosis (greater than 1000 x 10^9/L) unresponsive to therapy","valueDescription":"Persistent thrombocytosis (greater than 1000 x 10^9/L) unresponsive to therapy","ValueMeaning":{"publicId":"6584057","version":"1","preferredName":"Persistent thrombocytosis (greater than 1000 x 10^9/L) unresponsive to therapy","longName":"6584057","preferredDefinition":"Persistent thrombocytosis (greater than 1000 x 10^9/L) unresponsive to therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C70AFCA-0AE1-49C0-E053-F662850AB2D3","latestVersionIndicator":"Yes","beginDate":"2018-12-07","endDate":null,"createdBy":"LEEW","dateCreated":"2018-12-07","modifiedBy":"ONEDATA","dateModified":"2018-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C70AFCA-0AFA-49C0-E053-F662850AB2D3","beginDate":"2018-12-07","endDate":null,"createdBy":"LEEW","dateCreated":"2018-12-07","modifiedBy":"ONEDATA","dateModified":"2018-12-07","deletedIndicator":"No"},{"value":"Persistent or increasing WBC (greater than 10 x 10^9/L), unresponsive to therapy","valueDescription":"Persistent or increasing WBC (greater than 10 x 10^9/L), unresponsive to therapy","ValueMeaning":{"publicId":"6584058","version":"1","preferredName":"Persistent or increasing WBC (greater than 10 x 10^9/L), unresponsive to therapy","longName":"6584058","preferredDefinition":"Persistent or increasing WBC (greater than 10 x 10^9/L), unresponsive to therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C70AFCA-0B04-49C0-E053-F662850AB2D3","latestVersionIndicator":"Yes","beginDate":"2018-12-07","endDate":null,"createdBy":"LEEW","dateCreated":"2018-12-07","modifiedBy":"ONEDATA","dateModified":"2018-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C70AFCA-0B1D-49C0-E053-F662850AB2D3","beginDate":"2018-12-07","endDate":null,"createdBy":"LEEW","dateCreated":"2018-12-07","modifiedBy":"ONEDATA","dateModified":"2018-12-07","deletedIndicator":"No"},{"value":"Occurrence of 2 or more mutations in BCR-ABL1 during TKI therapy","valueDescription":"Occurrence of 2 or more mutations in BCR-ABL1 during TKI therapy","ValueMeaning":{"publicId":"7575473","version":"1","preferredName":"Occurrence of 2 or more mutations in BCR-ABL1 during TKI therapy","longName":"7575473","preferredDefinition":"Occurrence of 2 or more mutations in BCR-ABL1 during TKI therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA846DA3-84A0-5625-E053-4EBD850ABC62","latestVersionIndicator":"Yes","beginDate":"2021-02-04","endDate":null,"createdBy":"LEEW","dateCreated":"2021-02-04","modifiedBy":"ONEDATA","dateModified":"2021-02-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA846DA3-84B9-5625-E053-4EBD850ABC62","beginDate":"2021-02-04","endDate":null,"createdBy":"LEEW","dateCreated":"2021-02-04","modifiedBy":"ONEDATA","dateModified":"2021-02-04","deletedIndicator":"No"},{"value":"Any hematological, cytogenetic, or molecular indications of resistance to 2 sequential TKIs","valueDescription":"Any hematological, cytogenetic, or molecular indications of resistance to 2 sequential TKIs","ValueMeaning":{"publicId":"7575474","version":"1","preferredName":"Any hematological, cytogenetic, or molecular indications of resistance to 2 sequential TKIs","longName":"7575474","preferredDefinition":"Any hematological, cytogenetic, or molecular indications of resistance to 2 sequential TKIs","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA846DA3-84C3-5625-E053-4EBD850ABC62","latestVersionIndicator":"Yes","beginDate":"2021-02-04","endDate":null,"createdBy":"LEEW","dateCreated":"2021-02-04","modifiedBy":"ONEDATA","dateModified":"2021-02-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA846DA3-84DC-5625-E053-4EBD850ABC62","beginDate":"2021-02-04","endDate":null,"createdBy":"LEEW","dateCreated":"2021-02-04","modifiedBy":"ONEDATA","dateModified":"2021-02-04","deletedIndicator":"No"},{"value":"Hematologic resistance to the first TKI (or failure to achieve a complete hematologic response to the first TKI)","valueDescription":"Hematologic resistance to the first TKI (or failure to achieve a complete hematologic response to the first TKI)","ValueMeaning":{"publicId":"7575475","version":"1","preferredName":"Hematologic resistance to the first TKI (or failure to achieve a complete hematologic response to the first TKI)","longName":"7575475","preferredDefinition":"Hematologic resistance to the first TKI (or failure to achieve a complete hematologic response to the first TKI)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA846DA3-84E6-5625-E053-4EBD850ABC62","latestVersionIndicator":"Yes","beginDate":"2021-02-04","endDate":null,"createdBy":"LEEW","dateCreated":"2021-02-04","modifiedBy":"ONEDATA","dateModified":"2021-02-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA846DA3-84FF-5625-E053-4EBD850ABC62","beginDate":"2021-02-04","endDate":null,"createdBy":"LEEW","dateCreated":"2021-02-04","modifiedBy":"ONEDATA","dateModified":"2021-02-04","deletedIndicator":"No"},{"value":"Provisional response to TKI","valueDescription":"Provisional response to TKI","ValueMeaning":{"publicId":"7575395","version":"1","preferredName":"Provisional response to TKI","longName":"7575395","preferredDefinition":"Provisional response to TKI","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA75BBD0-B17D-3831-E053-4EBD850AF77D","latestVersionIndicator":"Yes","beginDate":"2021-02-03","endDate":null,"createdBy":"LEEW","dateCreated":"2021-02-03","modifiedBy":"ONEDATA","dateModified":"2021-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA75BBD0-B196-3831-E053-4EBD850AF77D","beginDate":"2021-02-03","endDate":null,"createdBy":"LEEW","dateCreated":"2021-02-03","modifiedBy":"ONEDATA","dateModified":"2021-02-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77CD6FA1-20C3-3BAF-E053-F662850ACA8E","latestVersionIndicator":"Yes","beginDate":"2018-10-09","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-09","modifiedBy":"LEEW","dateModified":"2021-02-04","changeDescription":"AAML18P1","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Accelerated phase criteria:","type":"Preferred Question Text","description":"Accelerated phase criteria:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77CD7C37-7441-3BA0-E053-F662850AB307","latestVersionIndicator":"Yes","beginDate":"2018-10-09","endDate":null,"createdBy":"LEEW","dateCreated":"2018-10-09","modifiedBy":"LEEW","dateModified":"2018-11-14","changeDescription":"AAML18P1","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}